Colloid Improves Organs Function in Resuscitation of Extensive Burn Patients
Launched by TANG-DU HOSPITAL · Sep 5, 2013
Trial Information
Current as of May 11, 2025
Completed
Keywords
ClinConnect Summary
Extensive burn patients are some of the most challenging critically ill patients who may have multiple-system organ failure with life-threatening complications.Over time, several resuscitation formulae have been proposed to guide burn resuscitation and the best known ones are Parkland and Evans formulae. The main controversy between the two formulae also focuses on whether to infuse the colloid in the first 24 h.Controversy continues and the conflicting results left many clinicians unsure about the effect of colloids on fluid resuscitation in extensive burn patients who suffer higher risk o...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • burn patients with total burn surface area ≥50% and full thickness burn surface area ≥30%.
- Exclusion Criteria:
- • age \<18 yrs, time between burn injury and fluid infusion \> 4 h, time arriving at our burn centre \> 6 h, pre-existing medical illnesses compromising the cardiopulmonary reserve or those need for compassionate care only.
About Tang Du Hospital
Tang-Du Hospital, affiliated with the Fourth Military Medical University, is a leading medical institution in China renowned for its comprehensive healthcare services and advanced research capabilities. As a prominent clinical trial sponsor, Tang-Du Hospital is committed to advancing medical science through rigorous clinical research. The hospital leverages its state-of-the-art facilities and a multidisciplinary team of experts to conduct innovative studies that aim to improve patient outcomes and contribute to the global medical community. With a strong emphasis on ethical standards and patient safety, Tang-Du Hospital is dedicated to fostering collaborations that enhance the development of new therapies and medical technologies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Xi'an, Shaanxi, China
Patients applied
Trial Officials
Xueyong Li, MD
Study Director
Department of Burn and Plastic Sugery
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials